论文部分内容阅读
PBI-4050, a novel first-in-class orally active low molecular weight compound, has been shown to exhibit anti-fibrotic and anti-inflammatory properties in different in vivo models, including acute and chronic kidney injuries, nonalcoholic steatohepatitis (NASH),myocardial infarction and idiopathic pulmonary fibrosis.